qCIOTechie_Healthcare_Analytics_BHE_Funding_healthIT_Technology

Healthcare Analytics Platform BHE Clinches USD78 Million For Its Instant Health Data Platform

Healthcare News

Healthcare_Analytics-Platform-BHE-Clinches-USD78-Million-For-Its-Instant-Health-Data-Platform Healthcare Analytics Platform BHE Clinches USD78 Million For Its Instant Health Data PlatformBHE, an innovative healthcare analytics company, has reportedly clinched a USD78 million minority growth investment to expand the development and market expansion of its real-world evidence analytics platform. BHE has received this fresh capital from Silversmith Capital Partners (Silversmith) and Leerink Transformation Partners (LTP). As per the announcement, the company plans to utilize this funding to speed up the development and market expansion of BHE’s flagship Instant Health Data (IHD) platform which is currently being utilized by more than two dozen major life science and research organizations.

Based in Boston, MA, BHE has been transforming the way analysts from interdisciplinary answer grave questions to make perceptive anticipations from large, intricate databases by leveraging leading IHD platform. Since BHE’s IHD platform announcement 6-year ago, it has driven the company’s growth rapidly. IHD, which is a fast, flexible and instinctive SaaS platform, enables life science company’s teams, health plans, and provider groups to deploy deep analytics with little-to-no programming required. It supports rapid analysis of more than 20 different real-world data sets, such as claims, electronic medical records, laboratory results, hospital, and integrated data sources.

According to Chief Technology Officer at BHE Jordan Menzin, “We are only at the tip of the iceberg in terms of the overall importance of RWE.” He further noted that “We are excited for this partnership, which will enable us to invest in significant product innovations necessary to serve the growing market need.  Importantly, new advances in data science can be leveraged to improve our ability to predict how patients may benefit from access to new treatment approaches.”